Lumito AB publishes year-end report 2025
Financial overviewFourth quarter 2025, 1 October – 31 DecemberNet sales amounted to 0 (79) KSEK.Result after taxes amounted to -11,244 (-15,476) KSEK.Earnings per share before and after dilution amounted to -0.01 (-0.06) SEK.Cash flow from operating activities amounted to -8,616 (-8,713) KSEK. Full year 2025, 1 January – 31 DecemberNet sales amounted to 0 (97) KSEK.Result […]
Lumito and Atlas Antibodies enter strategic partnership to advance high-resolution tissue imaging
Lumito AB (publ) (“Lumito” or the “Company”) and Atlas Antibodies AB (“Atlas Antibodies”) today announce a strategic partnership aimed at accelerating innovation in tissue analysis and strengthening their respective positions in a growing global market. By combining Lumito’s proprietary high-sensitivity imaging technology with Atlas Antibodies’ extensively validated antibody portfolio, the collaboration is designed to create […]
Invitation to webinar in connection with Lumito AB’s year-end report for 2025
Lumito AB (publ) (“Lumito” or the “Company”) will publish its year-end report for 2025 on 20 February 2026. In connection with the publication, shareholders, investors, and other stakeholders are invited to a webinar on the same day at 14:30 CET. During the session, the Company’s CEO, Sanna Wallenborg, will provide a brief introduction to Lumito and […]
Lumito initiates pilot project with leading professor in urological cancer research at Lund University
Lumito AB (publ) (“Lumito” or the “Company”) today announces that the Company is initiating a pilot project in collaboration with Professor Anders Bjartell, senior consultant and Professor of Urological Cancer Research at Lund University. The project aims to evaluate the Company’s technology for improved and earlier detection of lymph node metastases in prostate cancer, which […]
Lumito announces timetable for reverse share split and recalculated terms for outstanding warrants of series TO7
Extraordinary general meeting in Lumito AB (publ) ("Lumito" or the “Company") resolved on 20 January 2026 to carry out a reverse share split. Below, the Company announces the timetable for the reverse share split and the recalculated terms for warrants of series TO7. Reverse share split At the extraordinary general meeting in Lumito AB (publ) […]
Lumito receives patent approval in India
Lumito AB (publ) (“Lumito” or the “Company”) today announces that the Company has been granted a patent in India relating to its technology for tissue analysis using upconverting nanoparticles. The patent has previously been granted in Europe and the United States and further strengthens Lumito’s international intellectual property protection. The granted patent protects the technology […]
Two Swedish research customers place orders for Lumito’s SCIZYS Erbium Kit
Lumito AB (publ) (“Lumito” or the “Company”) today announces that two Swedish research customers have placed orders for the Company’s SCIZYS Erbium kit. The orders include the use of the Company’s Scan-as-a-Service offering and strengthen the Company’s position within the research segment. Both customers require the high sensitivity enabled by Lumito’s technology. The first order […]
Lumito’s technology presented at The Pathological Society of Great Britain & Ireland Winter Meeting 2026
Lumito AB (publ) (“Lumito” or the “Company”) today announces that its joint work together with Boston Cell Standards, was featured in a scientific poster presentation at the 2026 Winter Meeting of The Pathological Society of Great Britain & Ireland, which took place 20-21 January 2026. The poster, authored and presented by Keith Miller, focuses on […]
Changes to the Nomination Committee ahead of Lumito’s Annual General Meeting 2026
Lumito AB (publ) (“Lumito” or the “Company”) today announces that the composition of the Nomination Committee ahead of the Annual General Meeting 2026 has changed as a result of changes in the Company’s ownership structure. The composition of the Nomination Committee ahead of the Annual General Meeting 2026, based on ownership statistics from Euroclear Sweden […]
Analyst Group initiates coverage of Lumito
Lumito AB (publ) (”Lumito” or the “Company”) today announces that Analyst Group has initiated equity research coverage of Lumito, commissioned by the Company. The coverage includes equity research with quarterly updates as well as analyst comments on financial reports and press releases. Analyst Group’s full equity research report on the Company is expected to be […]